Eli Lilly’s M&A spree continues with acquisition of non-opioid pain drugmaker 4E
Eli Lilly is taking another shot at the pain market, continuing a recent M&A binge that shows no signs of slowing down.
Eli Lilly is taking another shot at the pain market, continuing a recent M&A binge that shows no signs of slowing down.